These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 16520998)

  • 1. Prescription of rh-APC differs substantially among western European countries.
    Schultz MJ; Levi M
    Intensive Care Med; 2006 Apr; 32(4):630-1. PubMed ID: 16520998
    [No Abstract]   [Full Text] [Related]  

  • 2. [Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis].
    Heslet L; Nielsen JD; Schierbeck J; Andersen JS
    Ugeskr Laeger; 2004 Mar; 166(11):997-1002. PubMed ID: 15049234
    [No Abstract]   [Full Text] [Related]  

  • 3. Activated protein C: do more survive?
    Ridley S
    Intensive Care Med; 2006 Apr; 32(4):608; author reply 610-2. PubMed ID: 16508755
    [No Abstract]   [Full Text] [Related]  

  • 4. Activated protein C: do more survive?
    Macias WL
    Intensive Care Med; 2006 Apr; 32(4):605-7; author reply 610-2. PubMed ID: 16508756
    [No Abstract]   [Full Text] [Related]  

  • 5. [Medical-economic evaluation of severe sepsis].
    Guidet B
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():28-30. PubMed ID: 15359937
    [No Abstract]   [Full Text] [Related]  

  • 6. Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated).
    McEvoy M
    Am J Crit Care; 2003 Sep; 12(5):398; author reply 398. PubMed ID: 14503421
    [No Abstract]   [Full Text] [Related]  

  • 7. [Xigris and corticoids: what are the perspectives for the patient with severe sepsis?].
    Annane D
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():43-5. PubMed ID: 15359943
    [No Abstract]   [Full Text] [Related]  

  • 8. Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated).
    Morris PE
    Am J Crit Care; 2003 Mar; 12(2):94-7. PubMed ID: 12625165
    [No Abstract]   [Full Text] [Related]  

  • 9. Drotrecogin alfa (activated) in the treatment of severe sepsis.
    Vincent JL
    Expert Rev Anti Infect Ther; 2006 Aug; 4(4):537-47. PubMed ID: 17009934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xigris: reducing mortality in adult patients with severe sepsis.
    Larson AM
    Urol Nurs; 2002 Jun; 22(3):200-1. PubMed ID: 12087796
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical experience with xigris].
    Wyncoll D
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():46-7. PubMed ID: 15359944
    [No Abstract]   [Full Text] [Related]  

  • 12. Drotrecogin alpha (activated).
    Labbos J; Bradsher J; Kirkpatrick P
    Nat Rev Drug Discov; 2003 Jan; 2(1):13-4. PubMed ID: 12521028
    [No Abstract]   [Full Text] [Related]  

  • 13. [The FDA's questions].
    Opal S
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():20-2. PubMed ID: 15359935
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug for severe sepsis is withdrawn from market, fails to reduce mortality.
    Mitka M
    JAMA; 2011 Dec; 306(22):2439-40. PubMed ID: 22166598
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of activated protein C in the pathophysiology of severe sepsis.
    Dettenmeier P; Swindell B; Stroud M; Arkins N; Howard A
    Am J Crit Care; 2003 Nov; 12(6):518-24; quiz 525-6. PubMed ID: 14619357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Surgical patients with severe sepsis: first results of the PROWESS study. Demographic data].
    Montravers P; Blaise M
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():38-9. PubMed ID: 15359941
    [No Abstract]   [Full Text] [Related]  

  • 17. Should we be using activated protein C to treat severe sepsis?
    Eve RL; Duffy MR
    Br J Hosp Med (Lond); 2009 Aug; 70(8):484. PubMed ID: 19684544
    [No Abstract]   [Full Text] [Related]  

  • 18. Appraisal of treatment for severe sepsis in intensive care units.
    Burchell M; Ruiz F; Barnett D
    Ann R Coll Surg Engl; 2005 Jul; 87(4):283-4. PubMed ID: 16888847
    [No Abstract]   [Full Text] [Related]  

  • 19. Drotrecogin alfa (activated) in South African private hospital ICUs.
    Hodgson RE; Williams PG; Foden AP; Grolman D
    S Afr Med J; 2003 Jul; 93(7):474-5. PubMed ID: 12939910
    [No Abstract]   [Full Text] [Related]  

  • 20. Benefit of recombinant human activated protein C beyond 28-day mortality: there is more to life than death.
    Levi M
    Crit Care Med; 2003 Mar; 31(3):984-5. PubMed ID: 12627023
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.